GLOSTRUP, DENMARK--(Marketwire - March 18, 2009) -
Copenhagen, 18 March 2009
Announcement no. 2, 2009
Zealand Pharma A/S, a Denmark-based biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, today announced that it has received the prestigious 2008 European Research & Development Company of the Year Award from Frost & Sullivan, a global growth consulting firm. The Award will be presented at a ceremony held at London Zoo on March 19, 2009.
This recognition is the result of 400 hours of market analysis conducted by Frost & Sullivan industry analysts. Zealand Pharma A/S received the number one industry rank after investigation via market interviews and extensive secondary research.
“It is an honour to be recognized by Frost & Sullivan”, said David Solomon, CEO of Zealand Pharma A/S. “The European Research & Development Award highlights our company’s ongoing achievements in its path to commercializing peptide-based drugs that treat unmet medical need in the areas of diabetes, metabolism, cardiovascular disease and gastrointestinal disorders such as Crohn’s Disease”.
Zealand Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative peptide-based products that target indications of significant unmet clinical need and commercial potential. The company has a proven track record in bringing compounds fast and efficiently through early clinical development.
About the Frost & Sullivan Research & Development Company of the Year Award
Award Description
The Frost & Sullivan Award for Research & Development Company of the Year is given to the company that has demonstrated technological superiority within its industry. This Award recognizes the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.
Research Methodology
To choose the recipient of this Award, the analyst team tracks emerging and existing technologies, as well as R&D developments. This is accomplished through interviews with major market participants and extensive secondary research. Also considered are elements such as product launches, customer acceptance, penetration rates, and time to market. Finally, competitors are compared and ranked for relative position. Frost & Sullivan then presents the Award to the company that received the number one industry rank.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com.
# # # Further information Mogens Vang Rasmussen, Executive Vice President, Chief Operating Officer and Chief Financial Officer, IT & Communications Zealand Pharma A/S, Smedeland 36, DK-2600 Glostrup, Denmark T +45 4328 1200 F +45 4328 1212 E info@zp.dk www.zealandpharma.com
About Zealand Pharma
Zealand Pharma is a biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs. Zealand is one of the leaders within the peptide area, a growing market with significant drug development activities including treatment of metabolic and cardiovascular diseases. All of Zealand’s products target diseases and symptoms of significant unmet clinical need and commercial potential.
Since 1999, Zealand’s scientists have built a pipeline that includes five compounds in clinical development, three of which have been out licensed to major pharmaceutical companies (Sanofi-Aventis, Wyeth and Helsinn Healthcare). All Zealand’s compounds emerge from Zealand’s own drug discovery.
* AVE0010/ZP10, a pharmaceutical agent for the treatment of Type 2 Diabetes, has been out-licensed to Sanofi-Aventis, which is the world’s third largest pharmaceutical corporation with a strong diabetes franchise. Phase III clinical trials were initiated in May 2008. * GAP-134/ZP1609; a gap junction modifier that prevents both ventricular and atrial arrhythmias in animal models. With its oral formulation, the molecule represents a novel paradigm for the potential chronic prevention of atrial arrhythmias. US based pharmaceutical giant Wyeth Pharmaceutical is currently conducting Phase I trials in the US. * ZP1846 is an innovative treatment for prevention of chemotherapy-induced diarrhea, which may prevent discontinuation and dose modification during cancer chemotherapy. A Phase I clinical trial has been conducted in the USA. The compound has been partnered with Helsinn Healthcare SA. * ZP1848 is a novel paradigm for the treatment of Inflammatory Bowel Diseases (e.g. Crohn’s Disease). The compound is in Phase I clinical development.
In addition, Zealand has a rich and broad portfolio of pre-clinical projects targeting a variety of disease areas, including osteoporosis and obesity-related diabetes.
Zealand Pharma A/S is based in Copenhagen and has approximately 65 employees.
The Company’s investors include BankInvest Biomedical Venture, LD Pensions, Dansk Erhvervsinvestering and Sunstone Capital as well as the leading international biotech investors CDC Innovation and AGF Private Equity (both in Paris) and LSP (Amsterdam).
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
